Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Clermont Ferrand cedex 01, France Clinical Trials

A listing of Clermont Ferrand cedex 01, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

Fluorouracil Cisplatin Cetuximab and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery

OBJECTIVES: Primary - To determine the maximum tolerated dose of fluorouracil and cisplatin when administered with cetuximab concurrently with esophageal radiotherapy. (Phase I) - To determine the complete histological response rate (after surgical resection). (Phase II) Secondary - To determine progression-free survival and overall survival. (Phase II) - To determine …

Phase

0.0 miles

Learn More »

Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

Patients will be randomised to continue on TKI (same daily dose) versus one of the alternative novel treatment approaches. If a patient is not eligible for one of the treatments, he can be randomised for the options for which he is eligible. All treatment options may be open at all …

Phase

0.0 miles

Learn More »

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

The trial consists of two parts: PHASE I Part 1 is a phase I trial examining the combination of paclitaxel, carboplatin, durvalumab and oleclumab in order to define the recommended phase II dose (RP2D) of oleclumab in this treatment combination. The period for DLT evaluation is defined as the time …

Phase

0.0 miles

Learn More »

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts expansion will …

Phase

0.0 miles

Learn More »

A Study to Determine Dose Safety Tolerability and Efficacy of CC-220 Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has …

Phase

9.92 miles

Learn More »